Lupin received tentative FDA approval for generic Revefenacin Inhalation Solution, 175 mcg/3 mL unit-dose vials.
The product is bioequivalent to Mylan's Yupelri® for COPD maintenance treatment with $260.7M annual US sales.
This approval expands Lupin's respiratory portfolio and positions it to compete in the COPD treatment market.